Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy

2 Aug 2014

Abstract excerpt

Core binding factor acute myelogenous leukemia (CBF AML) constitutes 15% of adult AML and carries an overall good prognosis. CBF AML encodes two recurrent cytogentic abnormalities referred to as t(8;21) and inv (16). The two CBF AML entities are usually grouped together but there is a considerable clinical, pathologic and molecular heterogeneity within this group of diseases. Recent and ongoing studies are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25088818
DOI: 10.1002/ajh.23821

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapyPMID 25088818Read ↗

Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities.Semantic proximity Read ↗

Core-Binding Factor Acute Myeloid LeukemiaSemantic proximity Read ↗

Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?Semantic proximity Read ↗

‘Acute myeloid leukemia: a comprehensive review and 2016 update’Semantic proximity Read ↗

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemiaSemantic proximity Read ↗

Advances in acute myeloid leukemia.Semantic proximity Read ↗

Classification of acute myeloid leukemiaSemantic proximity Read ↗

Core Binding Factor AML Beyond Favorable Risk: Molecular Heterogeneity, MRD Dynamics, and Implications for Clinical Decision-MakingSemantic proximity Read ↗

Core Binding Factor Acute Myeloid LeukemiaSemantic proximity Read ↗

Genetic abnormalities in core binding factor acute myeloid leukemia.Semantic proximity Read ↗

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual diseaseSemantic proximity Read ↗

The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.